Pharmacosmos A/S and Laboratoire Aguettant have signed an agreement under which Laboratoire Aguettant acquire the exclusive commercialisation rights to Monover® in France. Monover® is an innovative intravenous iron replacement therapy for the treatment of iron deficiency anaemia (IDA).
Monover® is an IV iron preparation with an innovative matrix structure that allows iron correction in one visit. Monover® has received marketing approval in France and is otherwise available in many other markets globally. Clinical studies on Monover® have been conducted with more than 3000 patients and over 5 million doses have been administered in clinical practice. The commercialisation agreement with Laboratoire Aguettant extends the availability of Monover® to one of Europe’s largest markets.
Terms of the agreement were not disclosed.
Eric Rougemond, Laboratoire Aguettant´s Chief Executive Officer said: "We are delighted to begin our partnership with Pharmacosmos A/S. Monover® is the result of both the expertise and commitment of Pharmacosmos A/S in the field of Iron replacement therapy. We are convinced that the strong reputation of Laboratoire Aguettant as a valued supplier of high quality and reliable speciality injectable pharmaceuticals to patients and healthcare professional will contribute to making Monover® a gold-standard for IDA management in France.”
Lars Christensen, Pharmacosmos' Chief Executive Officer, commented: "We look forward to working with Laboratoire Aguettant in France and believe that Monover® will serve yet unmet clinical needs with a clear potential to improve outcomes and convenience for French patients suffering from Iron Deficiency. Our agreement with Laboratoire Aguettant is an important milestone in our ambition to establish Monover® as a world leading brand for iron deficiency anaemia management."
VP Corporate Development & Strategy
Tobias S. Christensen
Headquartered in Denmark, Pharmacosmos is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use.
A research-based company, its ongoing R&D programme focuses on improving the lives of patients with iron deficiency with or without anaemia. More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. This makes it one of the largest global health challenges of our time.
Pharmacosmos has subsidiaries in US, UK, Ireland, Germany, Sweden and Norway and its products are marketed in more than 80 countries around the world. Its manufacturing facilities are approved, among others, by the Danish Medicines Agency and the US FDA.
You are now leaving Pharmacosmos.com. The website you are about to visit is is a Pharmacosmos subsidary. Do you want to proceed?